We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Wants Bioinformatic Approach to Evaluating Generic Drugs
FDA Wants Bioinformatic Approach to Evaluating Generic Drugs
The FDA is working on a new bioinformatic approach to evaluating the sameness of a generic drug’s active ingredient compared with that of the reference product.